Ms. Li Wang is President of LBX Pharmacy Chain Joint Stock Company. She was General Manager of the Strategic Investment Center & Executive Director of LBX Pharmacy Chain Joint Stock Company. She has Master...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xin Wan	Vice President	2.3yrs	CN¥1.31m	0.0052% CN¥ 683.4k
Shiyong Su	Vice President	3.5yrs	CN¥1.16m	0.0052% CN¥ 683.4k
Yufei Jiang	Vice President	3.3yrs	CN¥1.28m	0.0052% CN¥ 683.4k
Li Wang	President	no data	CN¥2.23m	0.013% CN¥ 1.7m
Lishan Chen	CFO & Head of Finance	less than a year	no data	no data
Shi Lei	Head of Accounting	no data	no data	no data
Shini Feng	Board Secretary	no data	CN¥820.00k	0.0098% CN¥ 1.3m
Wenshuai Zhang	Vice President	less than a year	no data	no data

2.3yrs

Average Tenure

42yo

Average Age

Experienced Management: 603883's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mingchuan Ren	Independent Director	less than a year	no data	no data
Lianfeng Wu	Independent Director	3.8yrs	CN¥100.00k	no data
Zilong Xie	Chairman	10.7yrs	CN¥2.16m	27.9% CN¥ 3.7b
Jiaqi Zheng	Director	no data	no data	no data
Bin Wu	Director	no data	CN¥100.00k	no data
Zhen Li	Director	2.6yrs	no data	no data
Bin Wu	Director	no data	no data	0.00025% CN¥ 32.7k
Qun Luo	Employee Supervisor	3.8yrs	no data	no data
Chee Kay Tse	Independent Director	2.8yrs	CN¥100.00k	no data

3.3yrs

Average Tenure

56yo

Average Age

Experienced Board: 603883's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/31 12:51
End of Day Share Price	2024/12/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

LBX Pharmacy Chain Joint Stock Company is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yue Gao	Changjiang Securities Co. LTD.
Qianyi Li	China International Capital Corporation Limited
Bing Zhao	China Renaissance Securities

LBX Pharmacy Chain Management

Management criteria checks 2/4

Key information

Recent management updates

LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2024 Results on Apr 30, 2025

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Consensus EPS estimates increase by 13%

We Think You Can Look Beyond LBX Pharmacy Chain's (SHSE:603883) Lackluster Earnings

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥0.33 per share

LBX Pharmacy Chain Joint Stock Company to Report Q3, 2024 Results on Oct 30, 2024

Price target decreased by 12% to CN¥26.64

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates fall by 29%

LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Right But Growth Is Lacking After Shares Rocket 30%

New minor risk - Share price stability

Investor sentiment improves as stock rises 23%

Now 23% undervalued after recent price drop

Is LBX Pharmacy Chain (SHSE:603883) Using Too Much Debt?

Take Care Before Jumping Onto LBX Pharmacy Chain Joint Stock Company (SHSE:603883) Even Though It's 30% Cheaper

Investor sentiment deteriorates as stock falls 17%

LBX Pharmacy Chain Joint Stock Company to Report First Half, 2024 Results on Aug 30, 2024

Dividend increased to CN¥0.66

Here's Why We Think LBX Pharmacy Chain (SHSE:603883) Is Well Worth Watching

LBX Pharmacy Chain Joint Stock Company, Annual General Meeting, Jun 13, 2024

LBX Pharmacy Chain (SHSE:603883) Seems To Use Debt Quite Sensibly

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

There Is A Reason LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Price Is Undemanding

LBX Pharmacy Chain Joint Stock Company to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment improves as stock rises 18%

LBX Pharmacy Chain Joint Stock Company to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥1.36 (vs CN¥1.26 in FY 2021)

Now 21% undervalued after recent price drop

Price target increased by 8.1% to CN¥45.36

Now 21% undervalued after recent price drop

Price target increased by 7.5% to CN¥43.11

Price target increased to CN¥41.97

Now 22% undervalued

Now 21% undervalued

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥58.58

Consensus EPS estimates fall by 21%

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CN¥63.49

Less than half of directors are independent

Third quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.34 in 3Q 2020)

LBX Pharmacy Chain Joint Stock Company (SHSE:603883) agreed to acquire 51% stake in Hebei Hua Tuo Pharmacy Medicine Chain Co., Ltd. from Zhang Weijun, Tian Jinping, Ma Zhirong and Guo Zhihong fro CNY 1.4 billion.

Price target decreased to CN¥75.25

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.35 in 2Q 2020)

Price target decreased to CN¥79.67

Price target decreased to CN¥86.50

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.49 in 1Q 2020)

New 90-day low: CN¥61.85

New 90-day high: CN¥81.64

Investor sentiment improved over the past week

New 90-day low: CN¥63.60

New 90-day low: CN¥65.89

New 90-day low: CN¥67.21

Price target raised to CN¥97.98

Laobaixing Reportedly in Merger Talks with Yixintang

Third quarter earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report Q3, 2020 Results on Oct 30, 2020

Price target raised to CN¥89.75

New 90-day high - CN¥87.00

New 90-day high - CN¥87.00

First half earnings released

Laobaixing Pharmacy Chain Joint Stock Company to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensation

Leadership Team